Glenmark Pharmaceuticals Ltd

Glenmark Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glenmark Pharmaceuticals Ltd

₹ 2,275 -4.61%
29 May - close price
glenmarkpharma.com BSE: 532296 NSE: GLENMARK
About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Key Points

Leadership[1]

<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>
Website BSE NSE
  • Market Cap ₹ 64,198 Cr.
  • Current Price ₹ 2,275
  • High / Low ₹ 2,474 / 1,448
  • Stock P/E 40.1
  • Book Value ₹ 856
  • Dividend Yield 0.11 %
  • ROCE 6.51 %
  • ROE 6.58 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 2.66 times its book value
  • The company has delivered a poor sales growth of 2.21% over past five years.
  • Company has a low return on equity of 6.96% over last 3 years.
  • Working capital days have increased from 53.2 days to 92.2 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty Midcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,939 2,144 2,233 1,365 2,148 2,330 2,636 2,251 2,010 2,395 1,539 2,360 2,147
1,721 1,659 1,790 1,549 1,651 1,698 1,857 1,757 1,669 1,667 1,717 1,864 2,115
Operating Profit 218 485 443 -184 497 631 779 494 341 728 -178 496 32
OPM % 11% 23% 20% -14% 23% 27% 30% 22% 17% 30% -12% 21% 1%
-425 18 54 234 5,933 56 83 129 -91 -254 -646 -68 -61
Interest 59 62 58 74 83 15 12 8 13 15 23 22 18
Depreciation 47 49 50 51 52 53 55 55 56 58 59 59 60
Profit before tax -313 392 389 -76 6,295 618 795 559 181 401 -906 347 -107
Tax % -56% 31% 22% -73% 27% 27% 25% 26% 18% 18% -18% 19% -31%
-137 272 302 -20 4,614 454 595 414 148 330 -739 282 -74
EPS in Rs -4.87 9.63 10.72 -0.72 163.50 16.08 21.09 14.66 5.24 11.70 -26.19 10.00 -2.62
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
5,086 6,115 7,989 5,520 6,305 6,713 7,568 8,142 8,221 7,891 9,226 8,440
3,618 4,349 5,089 4,417 4,977 5,407 5,676 6,453 6,748 6,649 6,982 7,363
Operating Profit 1,467 1,766 2,900 1,103 1,328 1,305 1,892 1,689 1,473 1,242 2,244 1,077
OPM % 29% 29% 36% 20% 21% 19% 25% 21% 18% 16% 24% 13%
-86 116 -89 326 954 624 469 1,044 490 6,238 177 -1,029
Interest 30 36 153 191 224 256 266 236 207 277 49 79
Depreciation 119 100 105 96 106 139 151 160 184 202 219 236
Profit before tax 1,232 1,747 2,553 1,143 1,952 1,535 1,944 2,337 1,572 7,001 2,154 -266
Tax % 18% 15% 16% 11% 17% 12% 15% 15% 23% 26% 25% -25%
1,008 1,484 2,141 1,014 1,622 1,355 1,649 1,998 1,209 5,167 1,610 -201
EPS in Rs 37.14 52.60 75.86 35.95 57.49 48.01 58.46 70.80 42.84 183.12 57.07 -7.12
Dividend Payout % 5% 4% 3% 6% 3% 5% 4% 4% 6% 1% 4% -35%
Compounded Sales Growth
10 Years: 3%
5 Years: 2%
3 Years: 1%
TTM: -9%
Compounded Profit Growth
10 Years: 1%
5 Years: 0%
3 Years: 0%
TTM: -8%
Stock Price CAGR
10 Years: 11%
5 Years: 31%
3 Years: 55%
1 Year: 56%
Return on Equity
10 Years: 10%
5 Years: 8%
3 Years: 7%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 27 28 28 28 28 28 28 28 28 28 28 28
Reserves 4,925 7,338 9,408 10,363 11,914 13,198 14,781 16,710 17,849 22,942 24,476 24,122
410 787 2,777 2,981 3,134 3,574 3,704 3,738 3,221 707 830 107
2,289 1,960 1,787 1,892 2,066 2,152 2,104 2,438 3,487 3,736 2,700 5,228
Total Liabilities 7,651 10,113 14,001 15,265 17,143 18,952 20,618 22,914 24,586 27,414 28,033 29,485
1,231 1,438 1,596 1,699 1,413 1,612 1,722 1,752 1,746 1,756 1,979 2,120
CWIP 294 276 271 420 286 200 131 109 172 198 155 67
Investments 1,660 1,858 1,867 3,213 3,269 4,714 6,990 8,559 10,334 12,965 15,195 15,202
4,466 6,541 10,267 9,933 12,174 12,426 11,774 12,494 12,334 12,496 10,705 12,096
Total Assets 7,651 10,113 14,001 15,265 17,143 18,952 20,618 22,914 24,586 27,414 28,033 29,485

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
145 355 878 1,124 2,490 1,579 1,243 1,216 1,474 -495 589
-176 -1,545 -2,580 -1,137 -2,256 -1,607 -1,235 -897 -432 3,197 -490
-32 1,223 1,879 -62 -155 -139 -81 -305 -978 -2,666 -95
Net Cash Flow -64 32 177 -75 79 -168 -73 14 64 35 3
Free Cash Flow -89 12 587 735 2,867 1,575 1,112 1,053 1,601 -690 249
CFO/OP 26% 41% 53% 128% 218% 147% 83% 95% 128% 30% 52%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 175 182 177 253 121 100 120 120 111 115 101 143
Inventory Days 161 182 172 195 141 115 94 102 117 130 156 153
Days Payable 343 306 221 273 258 217 201 208 225 307 242 326
Cash Conversion Cycle -6 59 129 175 4 -3 14 14 3 -62 15 -30
Working Capital Days 79 108 170 232 151 106 115 42 29 12 55 92
ROCE % 33% 26% 29% 10% 13% 11% 12% 11% 11% 10% 10% 7%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
ANDA Approvals (Annual)
Number

Log in to view insights

Please log in to see hidden values.

Login
ANDA Pending Approval
Number
Manufacturing Facilities
Number
US Portfolio (Authorized Generic Products)
Number
India Dealers/Distributors Count
Number
Market Share - India Cardiac Segment
%
Market Share - India Dermatology Segment
%
R&D Spend (as % of Sales)
%
Patents Granted (Cumulative)
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.64% 46.64% 46.65% 46.65%
25.51% 24.79% 23.71% 21.38% 20.98% 23.05% 23.51% 23.15% 20.62% 20.73% 19.20% 20.35%
9.10% 10.31% 10.92% 13.36% 13.93% 13.21% 13.85% 14.60% 17.64% 18.61% 20.09% 19.28%
0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
18.70% 18.21% 18.70% 18.58% 18.42% 17.06% 15.96% 15.56% 15.05% 13.97% 14.02% 13.70%
No. of Shareholders 2,36,9082,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,5841,96,105

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls